Skip to main
ANIP
ANIP logo

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals Inc is experiencing positive momentum, particularly in the ACTH gel market, with projected revenue growth driven by increased demand for its products, especially Cortrophin Gel and legacy brands. The company anticipates an improvement in adjusted operating margin, rising to 29.7% by 2028, alongside a robust forecast of generating over $630 million in operating cash flow from 2025 to 2028. Recent quarterly results demonstrated strong performance, with raises in full-year 2025 revenue estimates, reflecting both solid volume growth in new product launches and continued strength in their generics segment.

Bears say

ANI Pharmaceuticals has experienced significant revenue declines in its Brands segment during the second and third quarters of 2024 due to unfavorable market conditions affecting certain molecules, particularly Cortrophin, which faced recurrent pricing headwinds. Management is anticipating a steep decline of over 30% in 1Q 2025 revenues due to seasonal impacts and Medicare access issues, particularly influenced by non-profit foundations failing to secure adequate funding for co-pays. Despite achieving total revenues of $190.6 million in the previous quarter, 9% above expectations, ongoing challenges in market access and pricing erosion for key products raise considerable concerns regarding the sustainability of future earnings.

ANI Pharma (ANIP) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 13 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.